IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone
Recruitment status was: Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of this study is to determine the effects of a full dose (300 mg at hs) of oral micronized progesterone (OMP) on vasomotor symptoms [VMS] (hot flushes/night sweats), on forearm blood flow and on lipid levels and blood pressure in menopausal women without cardiovascular disease and with moderate to severe VMS.
The hypotheses are that progesterone will improve hot flushes, increase endothelium-dependent forearm blood flow and will decrease blood pressure without change in lipid levels.
| Condition | Intervention | Phase |
|---|---|---|
| Menopause | Drug: Oral Micronized Progesterone (Prometrium®) Other: Placebo | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment |
| Official Title: | Vasomotor Symptoms and Endothelial Function—A Randomized Placebo-controlled Trial of Oral Micronized Progesterone (Prometrium®) |
- Vasomotor symptoms prospectively recorded in the final month of therapy by therapy assignment, with pre-therapy baseline vasomotor symptoms as a covariate. [ Time Frame: Four months ]
- Forearm blood flow by plethysmography prospectively measured before and after three months of therapy [ Time Frame: Four months ]
- Other hormone-related quality of life measures on the Daily Menopause Diary®, especially self worth, sleep, and energy, recorded during the 4 months of the study. [ Time Frame: Four months ]
- Changes in two Quality of Life instruments - the Rand SF-36 and the Menopause-specific Quality of Life (MenQoL) questionnaires, measured at baseline and at the end of the study period [ Time Frame: Four months ]
- Lipid, blood pressure (BP), waist circumference and weight changes, measured at baseline and at the end of the study period [ Time Frame: Four months ]
| Estimated Enrollment: | 125 |
| Study Start Date: | September 2005 |
| Estimated Study Completion Date: | December 2012 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Oral micronized progesterone
|
Drug: Oral Micronized Progesterone (Prometrium®)
300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
Other Name: Oral micronized progesterone: Prometrium®, Uteroestan®
|
|
Placebo Comparator: 2
Placebo
|
Other: Placebo
3 identical placebo pills daily, no active ingredient.
|
Detailed Description:
In this 4-month study, menopausal women are randomized to either placebo or oral micronized progesterone (Prometrium®). Participants maintain a daily diary to keep track of their vasomotor symptoms and other factors. Forearm blood flow will be assessed by venous occlusion plethysmography at baseline and after three months of therapy. Screening tests at baseline to rule out heart disease include measurement of blood pressure and heart rate, electrocardiogram (ECG) and blood tests - fasting blood glucose and lipid profile.
Collection of serum and plasma samples at baseline and end of therapy for analysis of cardiovascular markers (e.g., c-reactive protein) and clotting and fibrinolytic markers. Continued daily diary collection for one month after therapy discontinuation to look for possible rebound effects. Analysis of outcomes will be by analysis of covariates, with final value as the outcome, therapy as factor and baseline values as covariate.
Eligibility| Ages Eligible for Study: | 40 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Menopausal women (final menstrual period one or more but less than 10 years before)
- No evidence of vascular disease (normal BP; without diabetes mellitus; normal cholesterol levels and non-smoker for at least a year; and normal ECG.)
- Moderate to severe VMS during the day and night.
Exclusion Criteria:
- Any menstruation in the preceding year.
- History of hysterectomy without ovariectomy unless 60 years of age.
- Use of ovarian hormone therapy (estrogen, progestin, progesterone or androgen) or selective estrogen receptor modulator (SERM) therapy (raloxifene or tamoxifen) in the preceding six months.
- Body mass index (BMI) over 35 or less than 20.
- Mean of several pre-treatment blood pressures over 145/95.
- Documented abnormal cholesterol; abnormal fasting capillary glucose; abnormal angiogram; ECG or exercise stress tests or a diagnosis of diabetes mellitus; or any history suggestive of angina.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00152438
| Canada, British Columbia | |
| Centre for Menstrual Cycle and Ovulation Research | |
| Vancouver, British Columbia, Canada | |
| Principal Investigator: | Jerilynn Prior | University of British Columbia |
More Information
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of British Columbia |
| ClinicalTrials.gov Identifier: | NCT00152438 History of Changes |
| Other Study ID Numbers: |
C03-0088 |
| Study First Received: | September 8, 2005 |
| Last Updated: | September 20, 2011 |
Keywords provided by University of British Columbia:
|
Vasomotor symptoms Menopause |
Additional relevant MeSH terms:
|
Progesterone Progestins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 28, 2017